Monopar Therapeutics Inc.

NasdaqCM:MNPR Stok Raporu

Piyasa değeri: US$81.0m

Monopar Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Monopar Therapeutics CEO'su Chandler Robinson, Dec2014 tarihinde atandı, in görev süresi 9.92 yıldır. in toplam yıllık tazminatı $ 1.78M olup, şirket hissesi ve opsiyonları dahil olmak üzere 32.6% maaş ve 67.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.09% ine doğrudan sahiptir ve bu hisseler $ 884.55K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.7 yıl ve 8.8 yıldır.

Anahtar bilgiler

Chandler Robinson

İcra Kurulu Başkanı

US$1.8m

Toplam tazminat

CEO maaş yüzdesi32.6%
CEO görev süresi9.9yrs
CEO sahipliği1.1%
Yönetim ortalama görev süresi5.7yrs
Yönetim Kurulu ortalama görev süresi8.8yrs

Son yönetim güncellemeleri

Recent updates

We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

Aug 13
We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

Is Monopar Therapeutics (NASDAQ:MNPR) In A Good Position To Deliver On Growth Plans?

Feb 27
Is Monopar Therapeutics (NASDAQ:MNPR) In A Good Position To Deliver On Growth Plans?

Will Monopar Therapeutics (NASDAQ:MNPR) Spend Its Cash Wisely?

Mar 02
Will Monopar Therapeutics (NASDAQ:MNPR) Spend Its Cash Wisely?

We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

Nov 16
We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

Monopar stock soars 19% as enrollment finishes in phase 2 part of oral mucositis study of Validive

Oct 05

We're Keeping An Eye On Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Rate

Jul 30
We're Keeping An Eye On Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Rate

Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans

Mar 28
Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Monopar Therapeutics (NASDAQ:MNPR) Will Use Its Cash Wisely

Jul 15
We're Hopeful That Monopar Therapeutics (NASDAQ:MNPR) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation

Mar 26
Here's Why We're Not Too Worried About Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation

Monopar nabs U.S. patent covering camsirubicin

Dec 22

Monopar Therapeutics selects targeted immuno-therapeutic candidate for COVID-19

Dec 10

Monopar launches validive mid-stage study in chemo-induced oral mucositis

Dec 08

Monopar Therapeutics EPS beats by $0.02

Nov 12

CEO Tazminat Analizi

Chandler Robinson'un ücretlendirmesi Monopar Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$7m

Mar 31 2024n/an/a

-US$8m

Dec 31 2023US$2mUS$580k

-US$8m

Sep 30 2023n/an/a

-US$9m

Jun 30 2023n/an/a

-US$10m

Mar 31 2023n/an/a

-US$10m

Dec 31 2022US$2mUS$550k

-US$11m

Sep 30 2022n/an/a

-US$10m

Jun 30 2022n/an/a

-US$10m

Mar 31 2022n/an/a

-US$10m

Dec 31 2021US$1mUS$525k

-US$9m

Sep 30 2021n/an/a

-US$9m

Jun 30 2021n/an/a

-US$8m

Mar 31 2021n/an/a

-US$7m

Dec 31 2020US$2mUS$504k

-US$6m

Sep 30 2020n/an/a

-US$5m

Jun 30 2020n/an/a

-US$4m

Mar 31 2020n/an/a

-US$4m

Dec 31 2019US$541kUS$386k

-US$4m

Sep 30 2019n/an/a

-US$4m

Jun 30 2019n/an/a

-US$4m

Mar 31 2019n/an/a

-US$4m

Dec 31 2018US$1mUS$375k

-US$3m

Sep 30 2018n/an/a

-US$3m

Jun 30 2018n/an/a

-US$17m

Mar 31 2018n/an/a

-US$17m

Dec 31 2017US$401kUS$331k

-US$17m

Tazminat ve Piyasa: Chandler 'nin toplam tazminatı ($USD 1.78M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 653.16K ).

Tazminat ve Kazançlar: Chandler şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.


CEO

Chandler Robinson (40 yo)

9.9yrs

Görev süresi

US$1,778,655

Tazminat

Dr. Chandler D. Robinson, M.D., MBA, MSc, Co-Founded Monopar Therapeutics Inc. in 2010 and has been Chief Executive Officer and Director since December 2014 and serves as President. Among his previous expe...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Christopher Starr
Co-Founder & Independent Executive Chairman of the Board9.9yrsUS$264.04k0.29%
$ 237.1k
Chandler Robinson
Co-Founder9.9yrsUS$1.78m1.09%
$ 884.5k
Andrew Cittadine
Chief Operating Officer3.4yrsUS$911.14k0.78%
$ 627.9k
Karthik Radhakrishnan
CFO, Principal Accounting Officer & Principal Financial Officerless than a yearVeri yok0.030%
$ 24.4k
Patrice Rioux
Acting Chief Medical Officer7.9yrsVeri yokVeri yok

5.7yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim: MNPR 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.7 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Christopher Starr
Co-Founder & Independent Executive Chairman of the Board9.9yrsUS$264.04k0.29%
$ 237.1k
Chandler Robinson
Co-Founder9.9yrsUS$1.78m1.09%
$ 884.5k
Michael Brown
Independent Director9.9yrsUS$126.04k0.92%
$ 743.0k
Raymond Anderson
Independent Director7.6yrsUS$136.54k0.10%
$ 84.6k
Arthur Klausner
Independent Director7.3yrsUS$128.54k0.12%
$ 97.2k
Kim Tsuchimoto
Director1.7yrsUS$848.44k0.22%
$ 180.9k

8.8yrs

Ortalama Görev Süresi

65.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: MNPR 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.8 yıldır).